Serial Number 79383112
Registration 7665567
700

Registration Progress

Application Filed
Jul 11, 2023
Under Examination
Approved for Publication
Dec 10, 2024
Published for Opposition
Dec 10, 2024
Registered
Jan 28, 2025

Trademark Image

Basic Information

Serial Number
79383112
Registration Number
7665567
Filing Date
July 11, 2023
Registration Date
January 28, 2025
Published for Opposition
December 10, 2024
Drawing Code
2

Status Summary

Current Status
Active
Status Code
700
Status Date
Jan 28, 2025
Registration
Registered
Classes
005 042 044

Rights Holder

Evox Therapeutics Limited

99
Address
Oxford Science Park, Medawar Centre,
2nd Floor East Building, Robert RobinsonAvenue Oxford, Oxfordshire OX4 4HG
GB

Ownership History

Evox Therapeutics Limited

Original Applicant
99
GB

Evox Therapeutics Limited

Owner at Publication
99
GB

Evox Therapeutics Limited

Original Registrant
99
GB

Legal Representation

Attorney
Nancy Sabarra

USPTO Deadlines

Next Deadline
1818 days remaining
Section 71 Declaration Due (Principal Register 66a) (Based on registration date 20250128)
Due Date
January 28, 2031
Grace Period Ends
July 28, 2031
Additional deadlines exist. Contact your attorney for complete deadline information.

Application History

25 events
Date Code Type Description Documents
Sep 5, 2025 FINO P FINAL DECISION TRANSACTION PROCESSED BY IB Loading...
Aug 14, 2025 FICS P FINAL DISPOSITION NOTICE SENT TO IB Loading...
Aug 14, 2025 FIMP P FINAL DISPOSITION PROCESSED Loading...
May 3, 2025 OPNX P NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB Loading...
Apr 28, 2025 FICR P FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB Loading...
Apr 15, 2025 OPNS P NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB Loading...
Apr 15, 2025 OPNR P NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB Loading...
Jan 28, 2025 NRCC E NOTICE OF REGISTRATION CONFIRMATION EMAILED Loading...
Jan 28, 2025 R.PR A REGISTERED-PRINCIPAL REGISTER Loading...
Dec 10, 2024 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Dec 10, 2024 PUBO A PUBLISHED FOR OPPOSITION Loading...
Dec 4, 2024 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Nov 15, 2024 CNSA O APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Oct 9, 2024 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Oct 9, 2024 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Oct 9, 2024 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Apr 30, 2024 RFNT P REFUSAL PROCESSED BY IB Loading...
Apr 10, 2024 RFCS P NON-FINAL ACTION MAILED - REFUSAL SENT TO IB Loading...
Apr 10, 2024 RFRR P REFUSAL PROCESSED BY MPU Loading...
Mar 22, 2024 RFCR E NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW Loading...
Mar 21, 2024 CNRT R NON-FINAL ACTION WRITTEN Loading...
Mar 20, 2024 DOCK D ASSIGNED TO EXAMINER Loading...
Nov 21, 2023 MAFR O APPLICATION FILING RECEIPT MAILED Loading...
Nov 17, 2023 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Nov 16, 2023 REPR M SN ASSIGNED FOR SECT 66A APPL FROM IB Loading...

Detailed Classifications

Class 005
Pharmaceuticals for the treatment of cancer, diabetes, obesity, metabolic syndrome, dementia, and other aging associated pathologies being mitochondrial disease, joint strain and tears, ligament strain and tears, muscle atrophy, muscular dystrophy, neuromuscular diseases, neurological disorders, neurodegenerative disorders, inflammatory disorders, infectious diseases, genetic diseases, rare diseases, in-born errors of metabolism (IEMs), lysosomal storage disorders, urea cycle disorders, liver disorders and diseases, brain diseases, eye disorders and diseases and lung disorders and diseases; pharmaceutical preparations and substances for the treatment of cancer, diabetes, obesity, metabolic syndrome, dementia, and other aging associated pathologies being mitochondrial disease, joint strain and tears, ligament strain and tears, muscle atrophy, muscular dystrophy, neuromuscular diseases, neurological disorders, neurodegenerative disorders, inflammatory disorders, infectious diseases, genetic diseases, rare diseases, in-born errors of metabolism (IEMs), lysosomal storage disorders, urea cycle disorders, liver disorders and diseases, brain diseases, eye disorders and diseases and lung disorders and diseases; pharmaceutical preparations, namely, a drug delivery system comprising genetically engineered or purified exosomes for therapeutic use; pharmaceutical preparations, namely, exosomes to deliver protein or nucleic acids or viral vectors for therapy; medicine for the treatment of cancer, diabetes, obesity, metabolic syndrome, dementia, and other aging associated pathologies being mitochondrial disease, joint strain and tears, ligament strain and tears, muscle atrophy, muscular dystrophy, neuromuscular diseases, neurological disorders, neurodegenerative disorders, inflammatory disorders, infectious diseases, genetic diseases, rare diseases, in-born errors of metabolism (IEMs), lysosomal storage disorders, urea cycle disorders, liver disorders and diseases, brain diseases, eye disorders and diseases and lung disorders and diseases; medical preparations for the treatment of cancer, diabetes, obesity, metabolic syndrome, dementia, and other aging associated pathologies being mitochondrial disease, joint strain and tears, ligament strain and tears, muscle atrophy, muscular dystrophy, neuromuscular diseases, neurological disorders, neurodegenerative disorders, inflammatory disorders, infectious diseases, genetic diseases, rare diseases, in-born errors of metabolism (IEMs), lysosomal storage disorders, urea cycle disorders, liver disorders and diseases, brain diseases, eye disorders and diseases and lung disorders and diseases; biological preparations for medical purposes for the treatment of cancer, diabetes, obesity, metabolic syndrome, dementia, and other aging associated pathologies being mitochondrial disease, joint strain and tears, ligament strain and tears, muscle atrophy, muscular dystrophy, neuromuscular diseases, neurological disorders, neurodegenerative disorders, inflammatory disorders, infectious diseases, genetic diseases, rare diseases, in-born errors of metabolism (IEMs), lysosomal storage disorders, urea cycle disorders, liver disorders and diseases, brain diseases, eye disorders and diseases and lung disorders and diseases; biological preparations for the treatment of cancer, diabetes, obesity, metabolic syndrome, dementia, and other aging associated pathologies in the nature of mitochondrial disease, joint and ligament strain and tears, muscle atrophy, muscular dystrophy, neuromuscular diseases, neurological disorders, neurodegenerative disorders, inflammatory disorders, infectious diseases, genetic diseases, rare diseases, in-born errors of metabolism (IEMs), lysosomal storage disorders and urea cycle disorders; biological preparations comprising exosome for the treatment of cancer, diabetes, obesity, metabolic syndrome, dementia, and other aging associated pathologies being mitochondrial disease, joint strain and tears, ligament strain and tears, muscle atrophy, muscular dystrophy, neuromuscular diseases, neurological disorders, neurodegenerative disorders, inflammatory disorders, infectious diseases, genetic diseases, rare diseases, in-born errors of metabolism (IEMs), lysosomal storage disorders, urea cycle disorders, liver disorders and diseases, brain diseases, eye disorders and diseases and lung disorders and diseases; biological preparations comprising a therapeutic target protein-loaded, nucleic acid-loaded or virus-loaded exosome for the treatment of genetic diseases, respiratory diseases, or cancer; biological preparations comprising exosome sold as a component of pharmaceuticals for the treatment of cancer, diabetes, obesity, metabolic syndrome, dementia, and other aging associated pathologies being mitochondrial disease, joint strain and tears, ligament strain and tears, muscle atrophy, muscular dystrophy, neuromuscular diseases, neurological disorders, neurodegenerative disorders, inflammatory disorders, infectious diseases, genetic diseases, rare diseases, in-born errors of metabolism (IEMs), lysosomal storage disorders, urea cycle disorders, liver disorders and diseases, brain diseases, eye disorders and diseases and lung disorders and diseases; biological reagents for medical use; mixed biological preparations for medical purposes for the treatment of cancer, diabetes, obesity, metabolic syndrome, dementia, and other aging associated pathologies being mitochondrial disease, joint strain and tears, ligament strain and tears, muscle atrophy, muscular dystrophy, neuromuscular diseases, neurological disorders, neurodegenerative disorders, inflammatory disorders, infectious diseases, genetic diseases, rare diseases, in-born errors of metabolism (IEMs), lysosomal storage disorders, urea cycle disorders, liver disorders and diseases, brain diseases, eye disorders and diseases and lung disorders and diseases; mixed biological preparations for the prevention and treatment of infectious diseases; diagnostic reagents for medical use; medical diagnostic reagents comprising exosome; pharmaceuticals, medicines, biologics, biotherapeutics, biosimilars and therapeutics, namely, extracellular vesicle (EV)-based nucleic acid therapeutics for the prevention and treatment of infections or disease, namely, cancer, diabetes, obesity, metabolic syndrome, dementia, and other aging associated pathologies being mitochondrial disease, joint strain and tears, ligament strain and tears, muscle atrophy, muscular dystrophy, neuromuscular diseases, neurological disorders, neurodegenerative disorders, inflammatory disorders, infectious diseases, genetic diseases, rare diseases, in-born errors of metabolism (IEMs), lysosomal storage disorders, urea cycle disorders, liver disorders and diseases, brain diseases, eye disorders and diseases and lung disorders and diseases; diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection; diagnostic kits comprised of medical diagnostic reagents and assays for testing of exosomes for use in disease detection; diagnostic kits comprised of medical diagnostic reagents and assays that test for the presence of cancer, diabetes, obesity, metabolic syndrome, dementia, and other aging associated pathologies in the nature of mitochondrial disease, joint and ligament strain and tears, muscle atrophy, muscular dystrophy, neuromuscular diseases, neurological disorders, neurodegenerative disorders, inflammatory disorders, infectious diseases, genetic diseases, rare diseases, in-born errors of metabolism (IEMs), lysosomal storage disorders and urea cycle disorders
Class 042
Scientific, medical and pharmaceutical research and development services; pharmaceutical drug development services; research and development of pharmaceutical preparations; research and analysis services, namely, those in the field of pharmaceuticals; biological research; clinical research in the field of transformational therapeutics; providing medical research and scientific research information in the field of filtration of exosomes from cultured cells or blood; scientific investigations for medical purposes; scientific laboratory services; medical research laboratory services; laboratory research services relating to pharmaceuticals; research and development in the field of biotherapeutics for the treatment of genetic diseases, cancer, diabetes, obesity, metabolic syndrome, dementia, and other aging associated pathologies such as mitochondrial disease, joint strain and tears, ligament strain and tears, muscle atrophy, muscular dystrophy, neuromuscular diseases, neurological disorders, neurodegenerative disorders, inflammatory disorders, infectious diseases, genetic diseases, rare diseases, in-born errors of metabolism (IEMs), lysosomal storage disorders and urea cycle disorders; consulting services in the fields of biotechnology, pharmaceutical research and development and genetic science; medical laboratory diagnostics research services; information, advisory and consultancy services relating to the aforesaid
Class 044
Medical services; medical and pharmaceutical consultancy; medical diagnostic services; medical analysis for the diagnosis and treatment of persons and medical examinations; medical treatment services; medical screening; medical monitoring, testing, inspection and analysis services relating to the diagnosis and treatment of cancer, viral and bacterial based infections and diseases; medical monitoring, testing, inspection and analysis services relating to the diagnosis and treatment of cancer, diabetes, obesity, metabolic syndrome, dementia, and other aging associated pathologies such as mitochondrial disease, joint and ligament strain and tears, muscle atrophy, muscular dystrophy, neuromuscular diseases, neurological disorders, neurodegenerative disorders, inflammatory disorders, infectious diseases, genetic diseases, rare diseases, in-born errors of metabolism (IEMs), lysosomal storage disorders and urea cycle disorders; information, advisory and consultancy services relating to the aforesaid

Additional Information

Design Mark
The mark consists of a circle formed by smaller overlapping circles in groups of two.

Classification

International Classes
005 042 044